How India Exports Brufen to the World

In the United States, ibuprofen is approved for over-the-counter (OTC) use and is listed in the FDA's Orange Book. The FDA has not issued any import alerts specifically targeting ibuprofen products from India as of March 2026. However, Import Alert 66-40, updated in February 2026, addresses drugs from firms that have not met Good Manufacturing Practices (GMPs), which could impact ibuprofen imports if compliance issues arise. Given the presence of 140 active Indian exporters, it is imperative for these entities to ensure strict adherence to FDA regulations to maintain market access.

In the European Union, ibuprofen is authorized for marketing by the European Medicines Agency (EMA) and is available both as a prescription and OTC medication, depending on the dosage. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) similarly regulates ibuprofen, ensuring compliance with safety and efficacy standards. Manufacturers exporting to these markets must comply with EU Good Manufacturing Practice (GMP) guidelines, which are harmonized across member states to ensure product quality and safety.

Ibuprofen is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in basic healthcare systems. The drug is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, ibuprofen is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for sale. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for ibuprofen formulations to ensure affordability; the latest revision was in January 2026. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for ibuprofen have long expired, leading to a competitive generic market. This has resulted in a proliferation of manufacturers and exporters, contributing to the significant export volume from India.

In March 2026, the FDA updated Import Alert 66-40, emphasizing the need for compliance with GMPs for drug imports, which could affect ibuprofen exporters. In January 2026, the NPPA revised the ceiling price for ibuprofen formulations to ensure continued affordability in the domestic market. Additionally, in February 2026, the EMA issued new guidelines on the labeling requirements for NSAIDs, including ibuprofen, to enhance patient safety and information clarity.

These developments highlight the dynamic regulatory environment affecting ibuprofen production and export, necessitating continuous monitoring and compliance by stakeholders.

India's pharmaceutical industry heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China, with estimates indicating that 70–80% of APIs and KSMs are sourced from Chinese manufacturers. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and environmental regulations in China. For instance, in 2018, the closure of approximately 145 API manufacturers in China due to stringent environmental norms led to significant supply disruptions and price escalations for Indian pharmaceutical companies.

To mitigate these risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic manufacturing of APIs and reduce reliance on imports. The scheme has led to increased investments in local API production, with commitments exceeding ₹4,570 crore by 2025. However, the full impact of these initiatives on reducing import dependency is yet to be realized.

The export data reveals a high supplier concentration, with the top five exporters accounting for 94.3% of Brufen exports. MYLAN LABORATORIES LIMITED alone contributes 55.0% of the total export value. Such concentration poses a single-source risk, where disruptions at a major supplier can significantly impact the entire supply chain. While the PLI scheme aims to diversify and strengthen domestic manufacturing capabilities, its effectiveness in addressing supplier concentration remains to be seen.

Recent geopolitical events have further strained pharmaceutical supply chains. In February 2026, the closure of the Strait of Hormuz due to escalating conflicts disrupted global shipping routes, leading to delays and increased costs for pharmaceutical exports from India. Additionally, tensions in the Red Sea region have forced shipping companies to reroute vessels, adding approximately 10 to 14 days to transit times and escalating freight costs. These disruptions have heightened concerns about the timely delivery of pharmaceutical products, including Brufen, to international markets.

• Diversify API and KSM Sources: Reduce dependency on Chinese imports by developing alternative supply chains, including sourcing from other countries and enhancing domestic production capabilities.

• Strengthen Supplier Base: Encourage the development of a broader supplier network to mitigate risks associated with high supplier concentration.

• Enhance Supply Chain Visibility: Implement advanced tracking and monitoring systems to identify and address potential disruptions proactively.

• Invest in Infrastructure: Improve domestic manufacturing infrastructure to support increased API and KSM production, aligning with the objectives of the PLI scheme.

• Develop Contingency Plans: Establish robust contingency strategies to manage geopolitical and shipping disruptions, ensuring continuity in supply chains.

RISK_LEVEL: HIGH